RT Journal Article
T1 Clinical effectiveness and safety of time-lapse imaging  systems for embryo incubation and selection in in-vitro  fertilisation treatment (TILT): a multicentre, three-parallel-group, double-blind, randomised controlled trial
A1 Bhide, Priya
A1 Chan, David Y L
A1 Lanz, Doris
A1 Alqawasmeh, Odai
A1 Barry, Eleanor
A1 Baxter, Dominic
A1 Gonzalez Carreras, Francisco
A1 Choudhury, Yasmin
A1 Cheong, Ying
A1 Pui Wah Chung, Jacqueline
A1 Collins, Bonnie
A1 Cong, Luping
A1 Doidge, Sally
A1 Heighway, James
A1 Patel, Deepali
A1 Pardo Llorente, M. Del Carmen
A1 Rattos, Annabel
A1 Wright, Annie
A1 Dodds, Julie
A1 Pérez Pérez, Teresa
A1 Khan, Khalid S
A1 Thangaratinam, Shakila
AB Background: Time-lapse imaging systems for embryo incubation and selection might improve outcomes of in-vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI) treatment due to undisturbed embryo culture conditions, improved embryo selection, or both. However, the benefit remains uncertain. We aimed to evaluate the effectiveness of time-lapse imaging systems providing undisturbed culture and embryo selection, and time-lapse imaging systems providing only undisturbed culture, and compared each with standard care without time-lapse imaging.Methods: We conducted a multicentre, three-parallel-group, double-blind, randomised controlled trial in participants undergoing IVF or ICSI at seven IVF centres in the UK and Hong Kong. Embryologists randomly assigned participants using a web-based system, stratified by clinic in a 1:1:1 ratio to the time-lapse imaging system for undisturbed culture and embryo selection (time-lapse imaging group), time-lapse imaging system for undisturbed culture alone (undisturbed culture group), and standard care without time-lapse imaging (control group). Women were required to be aged 18-42 years and men (ie, their partners) 18 years or older. Couples had to be receiving their first, second, or third IVF or ICSI treatment and could not participate if using donor gametes. Participants and trial staff were masked to group assignment, embryologists were not. The primary outcome was live birth. We performed analyses using the intention-to-treat principle and reported the main analysis in participants with primary outcome data available (full analysis set). The trial is registered on the International Trials Registry (ISRCTN17792989) and is now closed.Findings: 1575 participants were randomly assigned to treatment groups (525 participants per group) between June 21, 2018, and Sept 30, 2022. The live birth rates were 33·7% (175/520) in the time-lapse imaging group, 36·6% (189/516) in the undisturbed culture group, and 33·0% (172/522) in the standard care group. The adjusted odds ratio was 1·04 (97·5% CI 0·73 to 1·47) for time-lapse imaging arm versus control and 1·20 (0·85 to 1·70) for undisturbed culture versus control. The risk reduction for the absolute difference was 0·7 percentage points (97·5% CI -5·85 to 7·25) between the time-lapse imaging and standard care groups and 3·6 percentage points (-3·02 to 10·22) between the undisturbed culture and standard care groups. 79 serious adverse events unrelated to the trial were reported (n=28 in time-lapse imaging, n=27 in undisturbed culture, and n=24 in standard care).Interpretation: In women undergoing IVF or ICSI treatment, the use of time-lapse imaging systems for embryo culture and selection does not significantly increase the odds of live birth compared with standard care without time-lapse imaging.
PB Lancet Group
SN 01406736
YR 2024
FD 2024-07-20
LK https://hdl.handle.net/20.500.14352/112246
UL https://hdl.handle.net/20.500.14352/112246
LA eng
NO Bhide, P., Chan, D. Y., Lanz, D., Alqawasmeh, O., Barry, E., Baxter, D., ... & Thangaratinam, S. (2024). Clinical effectiveness and safety of time-lapse imaging systems for embryo incubation and selection in in-vitro fertilisation treatment (TILT): a multicentre, three-parallel-group, double-blind, randomised controlled trial. The Lancet, 404(10449), 256-265.
NO Barts Charity
NO Pharmasure Pharmaceuticals
NO Hong Kong OG Trust Fund
NO Hong Kong Health and Medical Research Fund
NO Hong Kong Matching Fund
DS Docta Complutense
RD 5 abr 2025